Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -57.27% | -139.07% | -76.68% | -105.60% | -276.97% |
| Total Depreciation and Amortization | 14.66% | 65.38% | 177.78% | 861.54% | 1,188.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 897.77% | 410.39% | 681.65% | 134.34% | 497.78% |
| Change in Net Operating Assets | -19.59% | 616.13% | 70.57% | -1,424.11% | 3,083.33% |
| Cash from Operations | -50.38% | -56.46% | -34.91% | -157.90% | -181.81% |
| Capital Expenditure | 100.00% | 89.57% | 93.98% | -83.21% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.39% | -- | -- | -- | -- |
| Cash from Investing | 103.36% | 1,900.56% | 2,347.47% | -69,291.97% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 225.00% | -- | -- | -- | 2,300.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 155.71% | 3,545.45% | -- | 2.11% | -14,100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 84.14% | 253.50% | 77.02% | -102.67% | -2,138.69% |